Through our blog, we hope to create a community where we can support and challenge each other through conversations, discussions and storytelling, and work together to move the field of oncology forward.

  • The Future of Personalized Cancer Care is Now

    Cancer immunotherapy has revolutionized how we view cancer treatment. When it works, the results are transformative. But right now, only a subset of people treated with immunotherapies respond. The ability to reliably identify both responders and non-responders to immunotherapy is one of the most important …

    Continue Reading

  • FoundationOne CDx™ is the first FDA-approved comprehensive genomic profiling assay and broad companion diagnostic for solid tumors. Find out how FoundationOne CDx can provide a broad range of biological insights and advantages. …

    Continue Reading

  • The Clinical Value of a Comprehensive Approach to Companion Diagnostics

    Genomic biomarkers have redefined how we treat cancer. By revealing the unique features of each person’s tumor, biomarkers often allow physicians to select highly specific therapies that are most likely to benefit their patients. As such, companion diagnostics that measure these biomarkers have become essential …

    Continue Reading

  • Informing precision treatment approaches for breast cancer with FoundationACT liquid biopsy

    Breast cancer is an important example of how a better understanding of cancer biology can lead to more personalized and precise treatments that improve patient care and prognosis. Surgery, hormone therapy, and chemotherapy were the standard of care for decades, but research into the HER2 gene as a potential …

    Continue Reading

  • New Data Suggest Tumor Mutational Burden Could Help Predict Response to Immunotherapy Across an Array of Tumor Types

    Tumor mutational burden (TMB) is a genomic biomarker with the potential to make a significant impact on the landscape of cancer immunotherapy. This emerging marker measures the number of mutations within a tumor genome and has already been shown to be associated with improved responses to checkpoint inhibitor …

    Continue Reading

  • Improving Clinical Trial Design with Tumor Mutational Burden

    Biomarkers are playing a transformative role in cancer drug development. Not only can they help identify patients most likely to respond to a medicine, they can also make a huge difference in drug development by improving outcomes in clinical trials. Just as the right biomarker can positively influence drug response …

    Continue Reading

  • Unleashing the Potential of Clinico-Genomic Information: ASCO 2017

    Precision oncology requires a robust understanding of how genomic information relates to clinical outcomes and treatment response. To make this connection, we need to integrate multiple sources of data into single databases that have the power to inform new clinical insights. This has historically been difficult …

    Continue Reading

  • Trials and Outcomes: Accelerating Precision Medicine at ASCO 2017

    At Foundation Medicine, our vision for precision oncology is based on fundamentally changing the way patients receive care. For us, this means enabling practical and clinically applicable solutions, no matter the stage or composition of the cancer, and regardless of where the patient lives or is being …

    Continue Reading

  • At ASCO 2017, Foundation Medicine is presenting new comprehensive genomic profiling data spanning 15 different tumor types. Learn more about the insights FoundationOne® can provide for both targeted therapies and immunotherapies across a range of different cancers. Learn more about our posters and presentations at …

    Continue Reading